Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
15 nov. 2022 06h30 HE
|
Affimed N.V.
AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a...
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
07 nov. 2022 08h05 HE
|
Affimed N.V.
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a...
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
04 nov. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
03 nov. 2022 09h15 HE
|
Affimed N.V.
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimed’s AFM13 in combination with cord blood-derived NK cells demonstrated...
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
03 nov. 2022 09h05 HE
|
Affimed N.V.
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an...
Affimed to Present at the 2022 Jefferies London Healthcare Conference
01 nov. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
05 oct. 2022 08h05 HE
|
Affimed N.V.
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presentedIn a second poster presentation, initial phase 1 dose escalation...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
04 sept. 2022 18h05 HE
|
Affimed N.V.
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable...
Affimed to Present at Upcoming Investor Conferences
01 sept. 2022 06h30 HE
|
Affimed N.V.
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
11 août 2022 06h30 HE
|
Affimed N.V.
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural killer (NK) cells: On track to report updated...